Sentences with phrase «with prostate cancer research»

Not exact matches

NEW YORK (360Dx)-- Biotech firm Berg continued its push into cancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperpcancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperpCancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperpcancer and benign prostate hyperplasia.

3) Reduced Risk Of Some Cancers — Although the connection is not fully understood, a significant body of research has linked high levels of calcium in the blood with fatal prostate cancer in men.

For instance, research has shown that combining cauliflower with curcumin (the active compound in the spice turmeric) may help prevent and treat prostate cancer.1

Only breast cancer and prostate cancer seem to have received much attention in the research world in connection with pumpkin seed intake, and much of that attention has been limited to the lignan content of pumpkin seeds.

Dr Catherine Pickworth from Cancer Research UK, said: «This early stage study adds to the growing evidence that some men with prostate cancer could benefit from being given PARP inhibitors alongside hormone deprivation treaCancer Research UK, said: «This early stage study adds to the growing evidence that some men with prostate cancer could benefit from being given PARP inhibitors alongside hormone deprivation treacancer could benefit from being given PARP inhibitors alongside hormone deprivation treatment.

The results from the Cancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone thCancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone thcancer, making abiraterone a first - line treatment alongside hormone therapy.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, a research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tCancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tcancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tumors.

«We show that high dietary saturated fat content is associated with increased prostate cancer aggressiveness,» said Emma H. Allott, PhD, a research assistant professor in the UNC Gillings School of Global Public Health.

David Agus, the research director of the Louis Warschaw Prostate Cancer Center and director of the Spielberg Family Center for Applied Proteomics, both at Cedars - Sinai Medical Center in Los Angeles, spent most of his time with end - of - life cancer patCancer Center and director of the Spielberg Family Center for Applied Proteomics, both at Cedars - Sinai Medical Center in Los Angeles, spent most of his time with end - of - life cancer patcancer patients.

«The phi test helps physicians distinguish prostate cancer from benign conditions by utilizing three different PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels,» said Kevin Slawin, MD, director, Vanguard Urologic Institute at Memorial Hermann Medical Group, clinical professor of Urology at Baylor College of Medicine and director of Urology, Memorial Hermann Hospital ‐ Texas Medical Center, who performed some of the key research that led to the development of the phi test and who also began using the test in February.

Dr Matthew Hobbs, Deputy Director of Research at Prostate Cancer UK said, «To greatly improve the survival chances of the 47,000 men diagnosed with prostate cancer each year, it's clear that we need to move away from the current one - size - fits - all approach to much more targeted treatment Prostate Cancer UK said, «To greatly improve the survival chances of the 47,000 men diagnosed with prostate cancer each year, it's clear that we need to move away from the current one - size - fits - all approach to much more targeted treatment meCancer UK said, «To greatly improve the survival chances of the 47,000 men diagnosed with prostate cancer each year, it's clear that we need to move away from the current one - size - fits - all approach to much more targeted treatment prostate cancer each year, it's clear that we need to move away from the current one - size - fits - all approach to much more targeted treatment mecancer each year, it's clear that we need to move away from the current one - size - fits - all approach to much more targeted treatment methods.

The research team used data from the recently published EORTC 22991 trial to study men with intermediate - risk prostate cancer randomized to either radiation therapy or radiation therapy and 6 months hormone therapy.

«These findings give us reason to rethink how we manage prostate cancer in men with known heart disease,» said Anthony D'Amico, MD, lead author of the research paper and chief of genitourinary radiation oncology at Brigham and Women's Hospital..

A drug used to treat men with late - stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (Cancer Institute at Oregon Health & Science University (OHSU).

The current authors evaluated the effects of ADT on mental and emotional well - being in men diagnosed with localized prostate cancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the Unitedprostate cancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the United Scancer using data from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the United SCancer of the Prostate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the UnitedProstate Strategic Urologic Research Endeavor) registry, which consists of data from largely community - based practices across the United States.

Recent years have seen extensive research on the genetics of prostate cancer, with over a hundred mutations identified, however most of these are only present in a small number of men.

The study, which appears online June 1, 2015 in the journal Cancer Prevention Research, offers insight on how diet may help improve survivorship for the nearly three million men living with prostate cancer in thCancer Prevention Research, offers insight on how diet may help improve survivorship for the nearly three million men living with prostate cancer in thcancer in the U.S.

Each man needs to work within his own limits, and each has different needs nutritionally,» said Focht, who wants to replicate the research with about 200 prostate cancer patients to see if the findings in this small pilot study hold true.

Last year the Imperial Cancer Research Fund (ICRF), Britain's second largest backer of cancer research, spent about Pounds sterling 100 000 on prostate cancer research, trifling compared with Pounds sterling 4.7 million on research into breast cCancer Research Fund (ICRF), Britain's second largest backer of cancer research, spent about Pounds sterling 100 000 on prostate cancer research, trifling compared with Pounds sterling 4.7 million on research into breastResearch Fund (ICRF), Britain's second largest backer of cancer research, spent about Pounds sterling 100 000 on prostate cancer research, trifling compared with Pounds sterling 4.7 million on research into breast ccancer research, spent about Pounds sterling 100 000 on prostate cancer research, trifling compared with Pounds sterling 4.7 million on research into breastresearch, spent about Pounds sterling 100 000 on prostate cancer research, trifling compared with Pounds sterling 4.7 million on research into breast ccancer research, trifling compared with Pounds sterling 4.7 million on research into breastresearch, trifling compared with Pounds sterling 4.7 million on research into breastresearch into breast cancercancer.

The work was funded by the Prostate Cancer Foundation, Stand Up To Cancer, Cancer Research UK, Prostate Cancer UK and the Movember Foundation, with support from the Investigator - Sponsored Study Collaboration between AstraZeneca and the National Cancer Research Network.

In a landmark paper, Cancer Research UK funded scientists alongside an international team of researchers read all of the DNA in tumor samples from 10 men with prostate cCancer Research UK funded scientists alongside an international team of researchers read all of the DNA in tumor samples from 10 men with prostate cancercancer.

The research, led by Daniel Krauss, M.D., a radiation oncologist, Beaumont Hospital — Royal Oak, found an association between positive post-radiation therapy biopsy results and subsequent clinical outcomes in men with localized prostate cancer.

Colin Collins and Alexander Wyatt, and other researchers from the Vancouver Prostate Centre at the Vancouver Coastal Health Research Institute, matched 25 patients» treatment outcomes with the RNA sequence of their prostate cancerProstate Centre at the Vancouver Coastal Health Research Institute, matched 25 patients» treatment outcomes with the RNA sequence of their prostate cancerprostate cancer tumors.

«This important research addressed a significant question in the care of patients with prostate cancer, showing the continued advancement in extending a good quality of life to those patients,» said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Instcancer, showing the continued advancement in extending a good quality of life to those patients,» said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer InstCancer Institute.

A multi-center study led by Fred Hutchinson Cancer Research Center has found that high - dose supplementation with both the trace element selenium and vitamin E increase the risk of high - grade prostate cCancer Research Center has found that high - dose supplementation with both the trace element selenium and vitamin E increase the risk of high - grade prostate cancercancer.

In contrast to studies that correlated elevated levels of IGF - 1 with the risk of developing prostate cancer, Greenberg's research showed that eliminating IGF - 1R expression in an otherwise normal mouse prostate caused the cells to proliferate and become hyperplastic.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sooWith enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients soowith immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients soowith potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patientsResearch Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatment and of the need for continued public support for research to bring these treatments to more patientsresearch to bring these treatments to more patients sooner.

(HealthDay)-- Males with BRCA mutations have increased incidence of malignant disease, specifically prostate, melanoma, pancreas, and breast cancers, according to a research letter published online April 12 in JAMA Oncology.

New research with mice has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.

Researchers at Karolinska Institutet, SciLifeLab and Centre for Clinical Research, Västerås have been able to explain why a combination of castration therapy and radiation therapy increases survival rates for patients with prostate cancer, compared to if they only receive radiation therapy.

Professor Ros Eeles from the Institute of Cancer Research and The Royal Marsden, who co-leads the prostate cancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop quCancer Research and The Royal Marsden, who co-leads the prostate cancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qucancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qucancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop quickly.

Long - term use of aspirin is associated with lower risk of dying from various types of cancers, including colorectal, lung, breast and prostate cancer, according to a study presented at the 2017 American Association for Cancer Research annual mecancer, according to a study presented at the 2017 American Association for Cancer Research annual meCancer Research annual meeting.

Previous research indicates that in the absence of PSA testing about 9 percent of all American men would be diagnosed with prostate cancer.

PCF created the Young Investigator Awards program with one goal: to identify a cohort of future research leaders who will keep the field of prostate cancer research vibrant with new ideas.

James Mohler, MD, Associate Director and Senior Vice President of Translational Research, received a three - year, $ 590,506 grant from the U.S. Department of Defense for his investigation into whether financial distress causes patients with prostate cancer to alter or delay treatment that may compromise survival.

Offit says that in his clinic, where the panel is already being used in research studies, he was able to test the daughter of a man with metastatic prostate cancer and learn that she carried mutations that put her at higher risk for ovarian cancer.

As with the asparagus, research has attributed anti-cancerous characteristics to avocados, especially preventing mouth, prostate and skin cancer.

Another research study found that a vegan diet along with support groups and lifestyle changes helped men with prostate cancer control the disease.

When I wrote my book «Fight Fat With Fat» and we had done some research, butter had come to the forefront because we found that butyric acid, which is the component of butter, can actually turn off oncogenes, cancer genes, particularly cancers regarding colon, certain lung, and prostate.

Excluding prostate cancer from the data, the research showed that for men with diabetes, there was a 9 percent increased risk of a cancer diagnosis.

With respect to prostate cancer, research shows no clear link that exercise may be preventative.

However, research has shown that men with certain risk factors are more likely than others to develop prostate cancer.

While doing some research on flax seeds, I discovered that flax seeds are one of the richest sources of alpha - linolenic acid; however, I then found some research asserting that «Dietary α - Linolenic Acid Is Associated with Reduced Risk of Fatal Coronary Heart Disease, but Increased Prostate Cancer Risk.»

There has been research and success with leukemia, colon, lung and skin, liver, and spleen, breast, prostate and testicular cancer.

These three lignans have a strong history of research in connection with reduced risk of several cancer types, including breast cancer, ovarian cancer, uterine cancer and prostate cancer.

Research has shown that selenium intake is associated with a reduced risk of prostate cancer.

Research suggests that taking a formula containing broccoli powder, turmeric powder, pomegranate whole fruit powder, and green tea extract three times daily for 6 months prevents an increase in prostate specific antigen (PSA) levels in men with prostate cancer.

For instance, research has shown that combining cauliflower with curcumin (the active compound in the spice turmeric) may help prevent and treat prostate cancer.

Contrary to the medical preference of chemically castrating men with prostate cancer, research with boron has shown that elevated testosterone levels are beneficial by shrinking prostate tumours and PSA levels, PSA being a marker for tumours and inflammation in the prostate.